NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq Biotechnology Index (Nasdaq: NBI), which will become effective prior to market open on Monday, December 21, 2020.
The Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Nasdaq®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).
The following 100 securities will be added to the Index:
| EXCHANGE | SYMBOL | COMPANY NAME |
| Nasdaq | ABUS | Arbutus Biopharma Corporation |
| Nasdaq | ADAP | Adaptimmune Therapeutics plc |
| Nasdaq | AKUS | Akouos, Inc. |
| Nasdaq | ALT | Altimmune, Inc. |
| Nasdaq | ALVR | AlloVir, Inc. |
| Nasdaq | ALXO | ALX Oncology Holdings Inc. |
| Nasdaq | AMTI | Applied Molecular Transport Inc. |
| Nasdaq | ANNX | Annexon, Inc. |
| Nasdaq | APLT | Applied Therapeutics, Inc. |
| Nasdaq | APRE | Aprea Therapeutics, Inc. |
| Nasdaq | ARCT | Arcturus Therapeutics Holdings Inc. |
| Nasdaq | ARQT | Arcutis Biotherapeutics, Inc. |
| Nasdaq | AVDL | Avadel Pharmaceuticals plc |
| Nasdaq | AZN | AstraZeneca PLC |
| Nasdaq | BDTX | Black Diamond Therapeutics, Inc. |
| Nasdaq | BEAM | Beam Therapeutics Inc. |
| Nasdaq | BNTX | BioNTech SE |
| Nasdaq | CABA | Cabaletta Bio, Inc. |
| Nasdaq | CALA | Calithera Biosciences, Inc. |
| Nasdaq | CDXS | Codexis, Inc. |
| Nasdaq | CLVS | Clovis Oncology, Inc. |
| Nasdaq | CNCE | Concert Pharmaceuticals, Inc. |
| Nasdaq | CNST | Constellation Pharmaceuticals, Inc. |
| Nasdaq | CRNX | Crinetics Pharmaceuticals, Inc. |
| Nasdaq | CRTX | Cortexyme, Inc. |
| Nasdaq | FMTX | Forma Therapeutics Holdings, Inc. |
| Nasdaq | FPRX | Five Prime Therapeutics, Inc. |
| Nasdaq | FREQ | Frequency Therapeutics, Inc. |
| Nasdaq | FULC | Fulcrum Therapeutics, Inc. |
| Nasdaq | FUSN | Fusion Pharmaceuticals Inc. |
| Nasdaq | GBIO | Generation Bio Co. |
| Nasdaq | GMDA | Gamida Cell Ltd. |
| Nasdaq | HARP | Harpoon Therapeutics, Inc. |
| Nasdaq | IDYA | IDEAYA Biosciences, Inc. |
| Nasdaq | IGMS | IGM Biosciences, Inc. |
| Nasdaq | IMAB | I-MAB |
| Nasdaq | IMUX | Immunic, Inc. |
| Nasdaq | IMVT | Immunovant, Inc. |
| Nasdaq | INZY | Inozyme Pharma, Inc. |
| Nasdaq | ISEE | IVERIC bio, Inc. |
| Nasdaq | ITOS | iTeos Therapeutics, Inc. |
| Nasdaq | JNCE | Jounce Therapeutics, Inc. |
| Nasdaq | KALA | Kala Pharmaceuticals, Inc. |
| Nasdaq | KALV | KalVista Pharmaceuticals, Inc. |
| Nasdaq | KDMN | Kadmon Holdings, Inc. |
| Nasdaq | KDNY | Chinook Therapeutics, Inc. |
| Nasdaq | KLDO | Kaleido Biosciences, Inc. |
| Nasdaq | KMDA | Kamada Ltd. |
| Nasdaq | KNSA | Kiniksa Pharmaceuticals, Ltd. |
| Nasdaq | KROS | Keros Therapeutics, Inc. |
| Nasdaq | KRYS | Krystal Biotech, Inc. |
| Nasdaq | KZR | Kezar Life Sciences, Inc. |
| Nasdaq | LEGN | Legend Biotech Corporation |
| Nasdaq | LRMR | Larimar Therapeutics, Inc. |
| Nasdaq | MDGL | Madrigal Pharmaceuticals, Inc. |
| Nasdaq | MNOV | MediciNova, Inc. |
| Nasdaq | MRNS | Marinus Pharmaceuticals, Inc. |
| Nasdaq | MRSN | Mersana Therapeutics, Inc. |
| Nasdaq | NK | NantKwest, Inc. |
| Nasdaq | NKTX | Nkarta, Inc. |
| Nasdaq | NLTX | Neoleukin Therapeutics, Inc. |
| Nasdaq | NRIX | Nurix Therapeutics, Inc. |
| Nasdaq | NVAX | Novavax, Inc. |
| Nasdaq | NXTC | NextCure, Inc. |
| Nasdaq | OCUL | Ocular Therapeutix, Inc. |
| Nasdaq | ODT | Odonate Therapeutics, Inc. |
| Nasdaq | ORIC | Oric Pharmaceuticals, Inc. |
| Nasdaq | OVID | Ovid Therapeutics Inc. |
| Nasdaq | PAHC | Phibro Animal Health Corporation |
| Nasdaq | PAND | Pandion Therapeutics Inc. |
| Nasdaq | PASG | Passage Bio, Inc. |
| Nasdaq | PCVX | Vaxcyte, Inc. |
| Nasdaq | PLRX | Pliant Therapeutics, Inc. |
| Nasdaq | PRTK | Paratek Pharmaceuticals, Inc. |
| Nasdaq | PRVB | Provention Bio, Inc. |
| Nasdaq | PSTX | Poseida Therapeutics, Inc. |
| Nasdaq | RAPT | RAPT Therapeutics, Inc. |
| Nasdaq | RDHL | Redhill Biopharma Ltd. |
| Nasdaq | REPL | Replimune Group, Inc. |
| Nasdaq | RLAY | Relay Therapeutics, Inc. |
| Nasdaq | RLMD | Relmada Therapeutics, Inc. |
| Nasdaq | RNA | Avidity Biosciences, Inc. |
| Nasdaq | RPRX | Royalty Pharma plc |
| Nasdaq | RPTX | Repare Therapeutics Inc. |
| Nasdaq | RVMD | Revolution Medicines, Inc. |
| Nasdaq | SELB | Selecta Biosciences, Inc. |
| Nasdaq | SMMT | Summit Therapeutics Inc. |
| Nasdaq | SNDX | Syndax Pharmaceuticals, Inc. |
| Nasdaq | SPRO | Spero Therapeutics, Inc. |
| Nasdaq | STRO | Sutro Biopharma, Inc. |
| Nasdaq | SURF | Surface Oncology, Inc. |
| Nasdaq | SWTX | SpringWorks Therapeutics, Inc. |
| Nasdaq | TCRR | TCR2 Therapeutics Inc. |
| Nasdaq | VIE | Viela Bio, Inc. |
| Nasdaq | VIR | Vir Biotechnology, Inc. |
| Nasdaq | VSTM | Verastem, Inc. |
| Nasdaq | VYNE | VYNE Therapeutics Inc. |
| Nasdaq | XENE | Xenon Pharmaceuticals Inc. |
| Nasdaq | ZIOP | ZIOPHARM Oncology Inc |
| Nasdaq | ZNTL | Zentalis Pharmaceuticals, Inc. |
As a result of the reconstitution, the following 16 securities will be removed from the Index:
| EXCHANGE | SYMBOL | COMPANY NAME |
| Nasdaq | ADMA | ADMA Biologics Inc |
| Nasdaq | AMRS | Amyris, Inc. |
| Nasdaq | AXNX | Axonics Modulation Technologies, Inc. |
| Nasdaq | CERS | Cerus Corporation |
| Nasdaq | CRBP | Corbus Pharmaceuticals Holdings, Inc. |
| Nasdaq | EOLS | Evolus, Inc. |
| Nasdaq | EYPT | EyePoint Pharmaceuticals, Inc. |
| Nasdaq | GLYC | GlycoMimetics, Inc. |
| Nasdaq | GRTS | Gritstone Oncology, Inc. |
| Nasdaq | LXRX | Lexicon Pharmaceuticals, Inc. |
| Nasdaq | NVCR | NovoCure Limited |
| Nasdaq | OPTN | OptiNose, Inc. |
| Nasdaq | PRQR | ProQR Therapeutics N.V. |
| Nasdaq | QTRX | Quanterix Corporation |
| Nasdaq | SLDB | Solid Biosciences Inc. |
| Nasdaq | TECH | Bio-Techne Corp |
About Nasdaq Global Indexes
Nasdaq Global Indexes has been creating innovative, market-leading, transparent indexes since 1971. Today, our index offering spans geographies and asset classes and includes diverse families such as the Dividend and Income (includes Dividend Achievers), Dorsey Wright, Fixed Income (includes BulletShares®), Global Equity, Green Economy, Nordic and Commodity indexes. We continuously offer new opportunities for financial product sponsors across a wide-spectrum of investable products and for asset managers to measure risk and performance. Nasdaq also provides exchange listing, custom index and design solutions to financial organizations worldwide.
About Nasdaq
Nasdaq (Nasdaq: NDAQ) is a global technology company serving the capital markets and other industries. Our diverse offering of data, analytics, software and services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on Twitter @Nasdaq, or at www.nasdaq.com.
Media Relations Contact
Emily Pan
(646) 637-3964
emily.pan@nasdaq.com
Issuer & Investor Contact
Index Client Services
indexservices@nasdaq.com
The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular financial product or an overall investment strategy. Neither Nasdaq, Inc. nor any of its affiliates makes any recommendation to buy or sell any financial product or any representation about the financial condition of any company or fund. Statements regarding Nasdaq’s proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.
- NDAQG-